The team is spearheaded by Hussein Yassine, MD, director of CPBH, whose research centers on the molecular underpinnings of neurodegenerative disorders. This initiative represents a significant step forward in understanding the mechanistic role of calcium-dependent phospholipase A2 (cPLA2), an enzyme whose elevated activity has been correlated with increased risk of dementia in APOE4 carriers. Their work has unveiled promising pathways to modulate cPLA2, potentially halting the deleterious inflammatory processes before irreversible neuronal damage occurs.

Bolstering these efforts, the Norman and Mary Pattiz Foundation has contributed a generous $3 million endowment to the Keck School of Medicine at USC. This philanthropic gift establishes the Norman and Mary Pattiz Alzheimer’s Research Fund, a resource dedicated to accelerating cutting-edge research efforts with an emphasis on early detection, innovative drug discovery, and nuanced exploration of neuroinflammation in Alzheimer’s. The infusion of capital will enable projects employing advanced imaging modalities and artificial intelligence techniques aimed at highlighting molecular targets involved in brain inflammation.

One of the fund’s pivotal initiatives is the establishment of a comprehensive registry to identify individuals at heightened risk for neuroinflammation, with particular attention to those harboring the APOE4 genetic variant combined with cardiovascular risk factors. This registry will serve as a critical platform for early intervention strategies, which are increasingly recognized as essential for preventing the progression of Alzheimer’s pathology before cognitive decline becomes apparent.

The fund will also prioritize modernization of the USC Alzheimer’s Disease Research Center’s (ADRC) brain pathology library. By enhancing the cataloging and analytical capacity around existing brain tissue samples, researchers can detect subtle markers of inflammation and neurodegeneration with greater precision. Such efforts are foundational for correlating pathological hallmarks with clinical phenotypes, significantly informing drug development pipelines.

Helena Chang Chui, MD, director of the ADRC and Raymond and Betty McCarron Professor of Neurology, emphasized the transformative potential of this partnership. She lauded the Norman and Mary Pattiz Foundation for their visionary support, which enables the ADRC to explore “bold hypotheses” regarding neuroinflammatory mechanisms, thereby fostering progress in the field of neurodegenerative disease research.

Karen Kerrigan, president of the Pattiz Foundation Board and former business manager of Norman Pattiz, articulated the Foundation’s commitment to honoring the legacy of its founders through pioneering research endeavors. The Foundation’s Board members, many of whom have personal connections to Alzheimer’s disease, share a unified vision to propel scientific breakthroughs that might lead to viable treatment options.

Recruitment of study participants will leverage two specialized registries at USC: GeneScreen, focusing on genetic risk profiling, particularly APOE4 carriers, and CPBH’s SPARK registry, which investigates lifestyle and health factors influencing brain aging and Alzheimer’s risk. These registries provide a powerful toolset for longitudinal study design and personalized intervention strategies.

Highlighting neuropathology as a cornerstone of Alzheimer’s research, the Foundation has endowed the Norman and Mary Pattiz Foundation Endowed Associate Professorship in Neuropathology. Anne Hiniker, MD, PhD, director of the USC ADRC Neuropathology Core, is the inaugural holder of this professorship. Her role involves detailed examination of over 1,100 brain tissue samples examining the progression of protein aggregates and inflammatory markers — hallmarks of Alzheimer’s pathology.

With the endowed professorship, Dr. Hiniker can dedicate significant research time to systematically cataloguing inflammatory signposts within brain specimens, potentially unearthing early indicators of disease onset and progression. Her work is expected to accelerate identification of viable therapeutic targets and facilitate translational research bridging basic science and clinical application.

Norman Pattiz’s background as a pioneering media entrepreneur, founder of the Westwood One radio syndicate, and a National Radio Hall of Fame inductee, reflects the visionary spirit the Foundation seeks to channel into Alzheimer’s research. Mary Turner Pattiz, known as “The Burner, Mary Turner,” was a celebrated radio personality who transitioned to clinical psychology, becoming a certified substance abuse counselor and influential leader in addiction recovery organizations.

The Foundation’s endowment honors Norman and Mary’s diverse legacies by investing in innovative scientific research aimed at understanding and eventually eradicating Alzheimer’s disease. As the disease continues to impact millions worldwide, such initiatives carry the promise of reshaping therapeutic approaches and redefining the future of neurodegenerative disease care.

Central to the scientific mission is the nuanced understanding that while the APOE gene, particularly its APOE4 allele, significantly elevates the risk of developing Alzheimer’s, it is not determinative. Dr. Yassine’s CPBH study demonstrated that elevated cPLA2 enzyme levels in APOE4 carriers correlate strongly with the emergence of dementia. The mechanistic insights from this work have paved the way for drug candidates capable of selectively targeting cPLA2 without compromising essential cellular functions.

The overarching goal is to identify neuroinflammatory pathways amenable to pharmacological intervention, thereby preventing or delaying the clinical onset of Alzheimer’s. The collaboration between CPBH, ADRC, and external funding sources like the Pattiz Foundation equips the scientific community with resources and multidisciplinary perspectives necessary to tackle this formidable disease from multiple angles.

“We are on the cusp of a paradigm shift,” summarizes Dr. Yassine. “The opportunity to interrogate enzyme activity, neuroinflammatory biomarkers, and gene-environment interactions in individuals at risk offers an unprecedented window for therapeutic innovation.” The commitment by the Pattiz Foundation fortifies this endeavor, underscoring the critical synergy between philanthropy and research excellence in addressing one of the most pressing health challenges of our time.

Subject of Research: Alzheimer’s Disease, Neuroinflammation, APOE4 Genetic Variant, Calcium-Dependent Phospholipase A2 (cPLA2), Early Detection and Prevention Strategies

Article Title: USC Researchers Pioneer Enzymatic Targets to Halt APOE4-Linked Neuroinflammation in Alzheimer’s Disease

News Publication Date: Not specified

Web References:
USC Scientists Identify Promising New Target for Alzheimer’s-Linked Brain Inflammation

Image Credits: Photo credit to USC

Keywords: Alzheimer disease, neurodegenerative diseases, dementia, brain, inflammation, neuroimaging, drug targets, drug discovery, genetic disorders

The genesis of this innovative research stretches back nearly two decades when Quitterer received invaluable brain tissue samples from patients undergoing tumor surgery at Ain Shams University Hospital in Cairo. These samples included individuals diagnosed with dementia alongside non-demented controls, offering a rare biological window into the molecular changes associated with Alzheimer’s. This access allowed her team to embark on comprehensive molecular investigations focused on understanding cellular processes going awry in dementia-afflicted brains.

At the heart of this research lies the enzyme G protein-coupled receptor kinase 2 (GRK2), a regulatory protein essential in modulating cellular responses to external stimuli in various tissues, including the heart and brain. GRK2 plays a crucial role in maintaining neuronal health by ensuring cells can react appropriately to stress and signaling cues. Despite its importance, GRK2’s involvement in Alzheimer’s pathology had remained relatively unexplored until the detailed analysis carried out by Quitterer’s team illuminated its critical function in the disease.

The researchers uncovered that GRK2 exists in two distinct forms within brain cells: one that is fully functional and active, and another that becomes inactivated by cellular metabolic processes. Strikingly, the inactivated form of GRK2 was found in elevated levels within the brains of Alzheimer’s patients, a trend corroborated in mouse models genetically predisposed to develop Alzheimer-like symptoms. This discovery highlighted a previously unrecognized pathological hallmark of the disease involving dysfunctional protein forms.

Further molecular scrutiny revealed that these inactivated GRK2 molecules do not remain dissolved within the cellular milieu. Instead, they aggregate into clusters that accumulate within neurons, forming deposits on the mitochondria—the cell’s energy generators. This aggregation compromises mitochondrial function by physically blocking mitochondrial pores, thereby stifling energy production and inducing intracellular stress. Such mitochondrial impairment is known to contribute broadly to neurodegenerative disease mechanisms, exacerbating neuronal dysfunction.

Even more compellingly, the presence of these GRK2 aggregates was shown to stimulate the overproduction of amyloid beta, a peptide central to Alzheimer’s disease pathology. Amyloid beta is notorious for forming plaques that disrupt synaptic communication and promote neuroinflammation. The research team observed that amyloid beta itself imposes additional stress on neurons, which in turn increases the formation of inactive and aggregated GRK2, creating a vicious feedback loop. This cyclical process accelerates cellular damage and advances disease progression.

To counter this detrimental cycle, Quitterer and her colleagues synthesized and tested multiple candidates capable of interrupting the aggregation of GRK2. Among these, Compound 10 emerged as a standout, demonstrating efficacy in both cultured cells and live animal models. This compound successfully inhibited GRK2 aggregation, thereby restoring mitochondrial functionality, reducing amyloid beta accumulation, and preserving neuronal viability. The treated mice showcased notably prolonged survival and delayed neurodegeneration compared to untreated controls.

Intriguingly, the benefits of Compound 10 extended beyond neurological improvements. The treated mice exhibited enhanced cardiac function and showed signs of decelerated systemic ageing, exemplified by a marked reduction in greying fur in older animals. These pleiotropic effects underscore the systemic nature of GRK2’s role and suggest potential wider applications of the compound in mitigating age-related physiological decline.

This research trajectory inherently required an extended timeline due to the complexities of Alzheimer’s disease modeling. Experimentation with older mice, which mimic the human aging process implicated in the disease, necessitated treatment windows spanning 18 to 24 months for meaningful and translatable results. Professor Quitterer noted that such temporal demands vastly exceed those typical in cancer research, explaining why advancements in Alzheimer’s therapeutics often unfold at a more measured pace.

Having secured patent protection for Compound 10, the ETH Zurich team is now seeking industrial partners equipped to propel this compound through the rigorous stages of drug development. This next phase will involve optimizing pharmacological profiles, safety assessments, and eventually clinical trials aimed at demonstrating efficacy in human patients. The hope is that Compound 10, either as a monotherapy or in combination with existing Alzheimer’s treatments, might substantially improve quality of life and cognitive longevity.

The identification of GRK2 as a novel molecular target distinguishes this approach from current therapeutic strategies, which largely focus on symptom management or amyloid beta clearance alone. By tackling an upstream pathological mechanism involving mitochondrial dysfunction and protein aggregation, Compound 10 represents a paradigm shift toward addressing root causes rather than downstream manifestations of Alzheimer’s disease.

While Alzheimer’s remains profoundly complex, this research injects renewed optimism into the field. The detailed mechanistic insights and promising animal data mark a significant milestone and open new avenues for drug discovery and development. Should these findings translate successfully to human patients, they could herald an era where Alzheimer’s progression is not only delayed but potentially mitigated at the molecular level.

In summary, Professor Ursula Quitterer’s team at ETH Zurich has elucidated a compelling role for GRK2 aggregation in Alzheimer’s disease pathology and developed Compound 10 as an effective inhibitor of this harmful process. This work lays foundational groundwork for innovative therapeutic interventions that address cellular energy deficits and protein aggregation cascades central to dementia progression. The scientific community and patients alike await forthcoming developments with great anticipation.

Subject of Research: Analysis of GRK2 aggregation in Alzheimer’s disease pathology and development of a therapeutic compound to inhibit this process.

Article Title: Analysis of GRK2 aggregation in the pathology of Alzheimer disease in animal models

News Publication Date: 21-Apr-2026

Web References: http://dx.doi.org/10.1016/j.xcrm.2026.102707

References: Research article published in Cell Reports Medicine

Keywords: Alzheimer’s disease, GRK2, protein aggregation, mitochondria, amyloid beta, neurodegeneration, Compound 10, dementia, molecular pharmacology, ETH Zurich

Dementia with Lewy bodies is a complex neurodegenerative disease marked by progressive cognitive decline, fluctuating attention, visual hallucinations, and parkinsonian motor symptoms. Despite advances in clinical diagnosis and symptomatic treatments, the molecular mechanisms driving selective vulnerability and regional brain deterioration remain insufficiently understood. The integration of high-resolution brain imaging with regional gene expression profiling presents a transformative approach to disentangle these mechanisms by linking anatomical changes to underlying molecular dysfunctions.

In this study, spearheaded by Habich, Baumann, Schwarz, and their colleagues, researchers employed imaging transcriptomics, a cutting-edge methodological framework that combines neuroimaging data with transcriptome maps. This approach helps pinpoint the locational alignment of gene expression patterns with observed cortical thinning and subcortical atrophy in DLB patients. By cross-referencing large-scale transcriptomic databases with structural MRI scans, the team delineated gene-brain atrophy correlations that shed light on region-specific susceptibilities.

One of the pivotal discoveries demonstrated that distinct clusters of genes involved in synaptic function, lysosomal activity, and proteostasis align spatially with regions exhibiting significant atrophic changes. Notably, genes implicated in alpha-synuclein metabolism—a hallmark protein aggregate in DLB—showed enriched expression within atrophy-prone areas. This reinforces the pathological relevance of alpha-synuclein’s misprocessing and accumulation in shaping neurodegenerative trajectories.

Moreover, the study revealed that brain regions with pronounced atrophy were enriched for gene sets regulating immune responses and neuroinflammation. These findings resonate with emerging literature positing neuroinflammation as a critical driver of neurodegeneration, suggesting a bidirectional interplay between immune activation and neuronal loss in the DLB brain. Importantly, this spatial-genetic linkage provides a tangible molecular signature that could be harnessed for biomarker development and personalized medicine.

A highlight of the research involves the identification of regionally selective vulnerability that could explain the clinical heterogeneity observed among DLB patients. By mapping transcriptomic landscapes onto atrophic patterns, investigators uncovered genetic profiles unique to vulnerable subcortical nuclei and cortical regions governing cognition and motor control. This granular insight paves the way for tailored interventions targeting region-specific molecular pathways.

Technological breakthroughs in multi-modal data integration underpinned the success of the study. High-resolution magnetic resonance imaging furnished precise quantifications of gray matter volume reductions, while publicly accessible brain transcriptome atlases enabled comprehensive gene expression mapping. Sophisticated bioinformatics pipelines coupled these datasets, allowing robust statistical inference while mitigating confounding factors such as age-related changes and comorbidities.

The implications extend far beyond academic understanding, as this approach could refine patient stratification in clinical trials. By incorporating individual genetic expression patterns correlated with neuroanatomical degeneration, clinicians may predict disease progression more accurately and optimize therapeutic strategies. This biomarker-driven framework marks a pivotal shift from symptomatic to mechanism-targeted treatments in DLB.

Furthermore, the findings challenge the traditional notion that neurodegeneration propagates uniformly across brain tissue. Instead, the study underscores that gene expression heterogeneity contributes decisively to which neuronal populations succumb or resist pathological insult. Recognizing this, future research might explore gene editing or modulation techniques in spatially defined circuits as potential disease-modifying therapies.

Beyond neurodegeneration, the imaging transcriptomic methodology showcased here holds promise for a spectrum of neurological disorders characterized by region-specific brain changes. Alzheimer’s disease, frontotemporal lobar degeneration, and even psychiatric illnesses such as schizophrenia could benefit from similar integrative analyses, potentially unraveling novel pathogenic pathways and therapeutic targets.

Despite its transformative potential, the research acknowledges limitations, including reliance on postmortem gene expression data from healthy brains, which may not fully recapitulate disease-altered transcriptional dynamics. Longitudinal studies incorporating patient-specific transcriptomics combined with in vivo neuroimaging could address these gaps and refine causative inferences.

In sum, this landmark imaging transcriptomics study presents a compelling framework that bridges the molecular and structural landscapes of dementia with Lewy bodies. By delineating the genetic signatures underpinning regional brain atrophy, the research illuminates the intricate molecular choreography driving neurodegeneration and opens promising therapeutic horizons. As technological capabilities evolve, integrating genotype, phenotype, and neuroimaging data stands to revolutionize our battle against complex brain disorders.

The study’s insights signal an exciting era in neuroscience where dissecting the molecular geography of the brain translates directly into clinical impact. With dementia prevalence rising globally and therapeutic progress lagging, such innovative interdisciplinary efforts provide a beacon of hope for patients, caregivers, and clinicians alike. The intersection of gene expression patterns and neuroanatomy charts a path toward precision neurology that could transform prognostic models and ultimately, patient care.

As further exploration into transcriptomic signatures within neurodegeneration accelerates, the anticipation builds for novel biomarker panels and gene-targeted therapeutics inspired by this study. The nexus of molecular biology and brain imaging not only decodes disease mechanisms but also personalizes intervention strategies at an individual brain region level. This paradigm shift could redefine diagnostics and treatments, heralding a future where dementia is more predictable, treatable, and one day possibly preventable.

The lasting contribution of this research lies in its elegant demonstration of how complex diseases like DLB emerge from the intricate interplay between genes and brain structure. It exemplifies how harnessing big data and computational neuroscience can yield profound biological insights previously inaccessible. The lessons learned here will undoubtedly spur similar integrative endeavors, accelerating discoveries across neurological and psychiatric landscapes.

Above all, this study mobilizes a fresh perspective on DLB—conceiving the brain not merely as a uniform organ vulnerable to global decline but as a mosaic of molecularly distinct areas whose selective degeneration orchestrates clinical symptomatology. This nuanced understanding empowers researchers and clinicians to envision precision interventions tailored to each patient’s unique molecular-neuroanatomical signature, fundamentally transforming neurology’s approach to neurodegenerative disease.

Subject of Research: Regional gene expression and brain atrophy in dementia with Lewy bodies.

Article Title: Regional gene expression and brain atrophy in dementia with Lewy bodies: an imaging transcriptomics study.

Article References:
Habich, A., Baumann, J.M., Schwarz, C.G. et al. Regional gene expression and brain atrophy in dementia with Lewy bodies: an imaging transcriptomics study. npj Parkinsons Dis. 12, 96 (2026). https://doi.org/10.1038/s41531-026-01355-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-026-01355-2